Search results for "AGENT"

showing 10 items of 8904 documents

European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference …

2008

This document summarizes the available evidence and provides recommendations on the use of home blood pressure monitoring in clinical practice and in research. It updates the previous recommendations on the same topic issued in year 2000. The main topics addressed include the methodology of home blood pressure monitoring, its diagnostic and therapeutic thresholds, its clinical applications in hypertension, with specific reference to special populations, and its applications in research. The final section deals with the problems related to the implementation of these recommendations in clinical practice. ispartof: Journal of Hypertension vol:26 issue:8 pages:1505-1530 ispartof: location:Neth…

medicine.medical_specialtySpecial populationsPhysiologybusiness.industryMEDLINEConsensus conferenceMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring Ambulatoryguidelinesarterial hypertension cardiovascular risk home blood pressure monitoringClinical PracticeEuropeHypertensionInternal MedicinemedicineHumansBlood pressure monitoringHypertension diagnosisDrug MonitoringCardiology and Cardiovascular MedicineIntensive care medicinebusinessAntihypertensive Agents
researchProduct

Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.

2014

The anticancer efficacy of anthracyclines is limited by cumulative dose-dependent early and delayed cardiotoxicity resulting in congestive heart failure. Mechanisms responsible for anthracycline-induced heart damage are controversially discussed and effective preventive measures are preferable. Here, we analyzed the influence of the lipid lowering drug lovastatin on anthracycline-induced late cardiotoxicity three month after treatment of C57BL/6 mice with five low doses of doxorubicin (5×3mg/kg BW; i.p.). Doxorubicin increased the cardiac mRNA levels of BNP, IL-6 and CTGF, while the expression of ANP remained unchanged. Lovastatin counteracted these persisting cardiac stress responses evoke…

medicine.medical_specialtyStatinCardiotonic AgentsAnthracyclinemedicine.drug_classBiologymedicine.disease_causeDNA MitochondrialInternal medicineNatriuretic Peptide Brainpolycyclic compoundsmedicineAnimalsDoxorubicinHSP70 Heat-Shock ProteinsLovastatinPharmacologyCardiotoxicityEjection fractionAntibiotics AntineoplasticInterleukin-6Gene Expression ProfilingMyocardiumConnective Tissue Growth Factormedicine.diseaseFibrosisCardiotoxicityMice Inbred C57BLEndocrinologyDoxorubicinHeart failureFemaleLovastatinOxidative stressmedicine.drugDNA DamagePharmacological research
researchProduct

Statin intolerance: new data and further options for treatment

2021

Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration of statins represents the cornerstone of the prevention and treatment of cardiovascular disease, with demonstrated long-term safety and efficacy. This review aims to revisit statin intolerance mechanisms, as well as to discuss new data and therapeutic options. Recent findings Although statins are well tolerated, myopathy and other adverse effects are a challenging problem, being the main reason for poor adherence to treatment and failure in lowering cardiovascular risk. Statin intolerance is the subject of ongoing research, as these drugs are widely used. There are alternative options o…

medicine.medical_specialtyStatinDosemedicine.drug_classHypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeHumansMedicinecardiovascular diseases030212 general & internal medicineRisk factorIntensive care medicineAdverse effectbusiness.industryCholesterolAnticholesteremic Agentsangiopoietin-like 3 protein inhibitors bempedoic acid ezetimibe proprotein convertase subtilisin-kexin type 9 inhibitors statin intolerance Cholesterol LDL Ezetimibe Humans Proprotein Convertase 9 Anticholesteremic Agents Cardiovascular Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemianutritional and metabolic diseasesCholesterol LDLEzetimibeRegimenchemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

The effect of ezetimibe on NAFLD

2015

NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common. The strong association between these conditions and the risk of cardiovascular disease make treatment crucial. Possible interventions for NAFLD target excess body weight, insulin resistance, inflammation, oxidative stress or intestinal lipid absorption. Administration of combination therapy with a statin plus ezetimibe, associated with lifestyle changes, may represent an effective strategy because of the strong reduction in low-density lipoprotein cholesterol levels. Combination therapy is often more effective, especially when complementary …

medicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classBioinformaticsLiver disorderInsulin resistanceEzetimibeInternal medicineInternal MedicineAnimalsHumansMedicinebusiness.industryAnticholesteremic AgentsIntestinal lipid absorptionnutritional and metabolic diseasesGeneral MedicineLipid Metabolismmedicine.diseaseEzetimibeTreatment OutcomeEndocrinologyCholesterolLiverAzetidinesDrug Therapy CombinationMetabolic syndromebusinessCardiology and Cardiovascular MedicineNon-alcoholic steatohepatitiDyslipidemiamedicine.drugNon-alcoholic fatty liver disease
researchProduct

P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel

2019

Abstract Background Statin intolerance is a clinical syndrome whereby adverse effects associated with statin therapy (most commonly muscle symptoms) result in the discontinuation of therapy. Statin discontinuation is associated with increased risk of adverse cardiac outcomes. Many patients who initially experience adverse effects are able to tolerate statin therapy to some extent. Careful stepwise diagnosis and management of individuals who experience adverse effects is essential to enable optimal reduction of cardiovascular risk. Purpose In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step by step approach to the diagnosis and practical management of sta…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classExpert opinionMedicineANTILIPEMIC AGENTSPosition paperCardiology and Cardiovascular MedicinebusinessIntensive care medicineLipid-lowering therapyEuropean Heart Journal
researchProduct

Rational for statin use in psoriatic patients

2013

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory pro…

medicine.medical_specialtyStatinmedicine.drug_classAtorvastatinDermatologyDiseasePharmacologychemistry.chemical_compoundPsoriasisInternal medicinemedicineAnimalsHumansPsoriasiscardiovascular diseasesSkinCholesterolbusiness.industrynutritional and metabolic diseasesPsoriasis Statins Cholesterol Atorvastatin Fluvastatin SimvastatinGeneral Medicinemedicine.diseaseTreatment OutcomechemistrySimvastatinlipids (amino acids peptides and proteins)Dermatologic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatin
researchProduct

GLP-1 receptor agonists in NAFLD.

2017

IF 4.101; International audience; Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

medicine.medical_specialtySteatosisEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesGastroenterologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyFibrosisWeight lossInternal medicineInternal MedicineHumansHypoglycemic AgentsMedicineReceptorGlucagon-like peptide 1 receptorGLP-1 receptor agonistsbusiness.industryFatty livernutritional and metabolic diseasesGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseFibrosisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030211 gastroenterology & hepatologytype 2 diabetesSteatosismedicine.symptombusinessNon-alcoholic fatty liver disease
researchProduct

Pharmacotherapy of female urinary incontinence

2005

Urinary incontinence is a major clinical problem and a significant cause of disability and dependency in older adults. Overall, the prevalence of urinary incontinence approaches 55% among women aged over 55 years. The past few years have seen significant advances in the pharmacotherapy of overactive bladder and stress incontinence. The review examines the evidence regarding their benefits and side-effects.

medicine.medical_specialtyStress incontinencebusiness.industryHealth StatusUrinary Incontinence StressAnti-Infective Agents UrinaryUrologyObstetrics and GynecologyEstrogensUrinary incontinenceMuscarinic AntagonistsMiddle Agedmedicine.diseaseAdrenergic AgonistsCholinergic AntagonistsPharmacotherapyOveractive bladderInternal medicineQuality of LifeHumansWomen's HealthMedicineFemalemedicine.symptombusinessBritish Menopause Society Journal
researchProduct

Erythropoietin and the heart: physiological effects and the therapeutic perspective.

2014

Erythropoietin (Epo) has been thought to act exclusively on erythroid progenitor cells. The identification of Epo receptor (EpoR) in non-haematopoietic cells and tissues including neurons, astrocytes, microglia, immune cells, cancer cell lines, endothelial cells, bone marrow stromal cells, as well as cells of myocardium, reproductive system, gastrointestinal tract, kidney, pancreas and skeletal muscle indicates that Epo has pleiotropic actions. Epo shows signals through protein kinases, anti-apoptotic proteins and transcription factors. In light of interest of administering recombinant human erythropoietin (rhEpo) and its analogues for limiting infarct size and left ventricular (LV) remodel…

medicine.medical_specialtyStromal cellCardiotonic AgentsAngiogenesisNeovascularization PhysiologicInflammationerythroid progenitor cellshemic and lymphatic diseasesInternal medicineEpo receptorReceptors ErythropoietinMedicineHumansErythropoietinCardioprotectionMicrogliabusiness.industryHeartErythropoietin receptorErythropoietin; Epo receptor; erythroid progenitor cellsEndocrinologymedicine.anatomical_structureErythropoietinCancer researchAirway RemodelingBone marrowmedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational journal of cardiology
researchProduct

Erythropoietin for Subarachnoid Hemorrhage: Is There a Reason for Hope?

2011

I b S a r a S ubarachnoid hemorrhage (SAH) associated with a ruptured cerebral aneurysm remains a source of significant morbidity and mortality, not only from the initial hemorrhage but lso from the delayed complications, such as cerebral vasospasm ften severe enough to induce irreversible changes in cerebral erfusion. Several drugs have been developed that have the otential to limit cerebral vasospasm and delayed ischemic eurologic deficit, thus improving outcome for patients. Howver, although numerous agents that can prevent arterial narrowng and/or block the excitatory cascade of events leading to schemic neuronal death in experimental conditions, there is still o pharmacologic agent tha…

medicine.medical_specialtySubarachnoid hemorrhageErythropoietin subarachnoid hemorrhageBlood volumeAneurysm RupturedNeuroprotectionAneurysmCerebral vasospasmInternal medicinemedicineErythropoietin; Neuroprotection; Subarachnoid hemorrhageHumansSubarachnoid hemorrhageErythropoietinSettore MED/27 - Neurochirurgiabusiness.industryEpoetin alfaPharmacologic Agentmedicine.diseaseRecombinant ProteinsNeuroprotectionEpoetin AlfaNeuroprotective AgentsErythropoietinCardiologySurgeryNeurology (clinical)businessmedicine.drug
researchProduct